Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland. more
Time Frame | NXTC | Sector | S&P500 |
---|---|---|---|
1-Week Return | -15.43% | 1.76% | -2.37% |
1-Month Return | -27.96% | 0.33% | -3.79% |
3-Month Return | -44.43% | -8.58% | -0.46% |
6-Month Return | -53.41% | -4.26% | 3.58% |
1-Year Return | -32.35% | 1.27% | 22.47% |
3-Year Return | -85.8% | 5.33% | 25.17% |
5-Year Return | -98.5% | 38.09% | 77.46% |
10-Year Return | -96.09% | 102.29% | 188.42% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 6.35M | 22.38M | - | - | - | [{"date":"2019-12-31","value":28.36,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Cost of Revenue | 34.22K | 46.55K | 4.30M | 4.48M | 3.68M | [{"date":"2019-12-31","value":0.76,"profit":true},{"date":"2020-12-31","value":1.04,"profit":true},{"date":"2021-12-31","value":95.98,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":82.23,"profit":true}] |
Gross Profit | 6.31M | 22.38M | (4.30M) | (4.48M) | (3.68M) | [{"date":"2019-12-31","value":28.21,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":-19.22,"profit":false},{"date":"2022-12-31","value":-20.02,"profit":false},{"date":"2023-12-31","value":-16.46,"profit":false}] |
Gross Margin | 99.46% | 100.00% | (Infinity%) | (Infinity%) | (Infinity%) | [{"date":"2019-12-31","value":99.46,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}] |
Operating Expenses | 43.83M | 63.60M | 70.77M | 75.91M | 67.64M | [{"date":"2019-12-31","value":57.74,"profit":true},{"date":"2020-12-31","value":83.79,"profit":true},{"date":"2021-12-31","value":93.22,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":89.1,"profit":true}] |
Operating Income | (37.48M) | (41.23M) | (70.77M) | (75.91M) | (67.64M) | [{"date":"2019-12-31","value":-3748200000,"profit":false},{"date":"2020-12-31","value":-4122500000,"profit":false},{"date":"2021-12-31","value":-7076500000,"profit":false},{"date":"2022-12-31","value":-7590900000,"profit":false},{"date":"2023-12-31","value":-6763700000,"profit":false}] |
Total Non-Operating Income/Expense | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Pre-Tax Income | (33.74M) | (36.60M) | (69.39M) | (74.73M) | (62.72M) | [{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3660300000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-7473300000,"profit":false},{"date":"2023-12-31","value":-6272300000,"profit":false}] |
Income Taxes | (3.75M) | (3.41M) | 6.96M | (5.30M) | - | [{"date":"2019-12-31","value":-53.81,"profit":false},{"date":"2020-12-31","value":-49.04,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-76.16,"profit":false},{"date":"2023-12-31","value":"-","profit":true}] |
Income After Taxes | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Income From Continuous Operations | (33.74M) | (36.60M) | (69.39M) | (74.73M) | (65.56M) | [{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3660300000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-7473300000,"profit":false},{"date":"2023-12-31","value":-6555600000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (33.74M) | (33.19M) | (69.39M) | (69.43M) | (62.72M) | [{"date":"2019-12-31","value":-3373700000,"profit":false},{"date":"2020-12-31","value":-3319000000,"profit":false},{"date":"2021-12-31","value":-6938900000,"profit":false},{"date":"2022-12-31","value":-6943300000,"profit":false},{"date":"2023-12-31","value":-6272300000,"profit":false}] |
EPS (Diluted) | (5.78) | (1.33) | (2.51) | (2.69) | (2.25) | [{"date":"2019-12-31","value":-578,"profit":false},{"date":"2020-12-31","value":-133,"profit":false},{"date":"2021-12-31","value":-251,"profit":false},{"date":"2022-12-31","value":-269,"profit":false},{"date":"2023-12-31","value":-225,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
NXTC | |
---|---|
Cash Ratio | 8.68 |
Current Ratio | 9.07 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
NXTC | |
---|---|
ROA (LTM) | -31.09% |
ROE (LTM) | -54.75% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
NXTC | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.16 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.84 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
NXTC | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 9.52 |
P/B | 0.30 |
Price/FCF | NM |
EV/R | 1.62 |
EV/Ebitda | 0.51 |
NextCure Inc (NXTC) share price today is $0.797
Yes, Indians can buy shares of NextCure Inc (NXTC) on Vested. To buy NextCure Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in NXTC stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of NextCure Inc (NXTC) via the Vested app. You can start investing in NextCure Inc (NXTC) with a minimum investment of $1.
You can invest in shares of NextCure Inc (NXTC) via Vested in three simple steps:
The 52-week high price of NextCure Inc (NXTC) is $2.57. The 52-week low price of NextCure Inc (NXTC) is $0.76.
The price-to-earnings (P/E) ratio of NextCure Inc (NXTC) is
The price-to-book (P/B) ratio of NextCure Inc (NXTC) is 0.30
The dividend yield of NextCure Inc (NXTC) is 0.00%
The market capitalization of NextCure Inc (NXTC) is $21.79M
The stock symbol (or ticker) of NextCure Inc is NXTC